Thrombembolie-Risikofaktoren und Prophylaxe

Zusammenfassung

Venöse Thromboembolien stellen eine wichtige Komplikation bei Tumorpatienten, da sie bei diesen Patienten gehäuft auftreten und eine relevante Morbidität bedingen. Das Risiko für thromboembolische Komplikationen bei Tumorpatienten liegt 3–9-mal höher als bei Nichttumorpatienten und stellt die zweithäufigste Todesursache bei Tumorpatienten dar. Das Thromboserisiko hängt neben der tumorinduzierten Koagulopathie von individuellen Faktoren, der Art und dem Stadium der Krebserkrankung, der Zeit seit der Krebsdiagnose sowie der Art einer systemischen Krebstherapie ab. Eine Thromboseprophylaxe bei Tumorpatienten ist wirksam, kann jedoch mit erhöhten Blutungen einhergehen. Auch wenn dezidierte Empfehlungen für einzelne Tumorentitäten aktuell nicht vorliegen, empfehlen internationale Leitlinien prophylaktische Maßnahmen bei Hochrisikopatienten. So kann ein Thromboserisiko von >8–10% als Indikation für eine Thromboseprophylaxe angesehen werden. Dieses Risiko wurde bei Patienten mit einem Khorana-Score von ≥2 erreicht und sollte individuell mithilfe der Nomogramme berechnet werden. Vor allem bei Patienten mit geringem Blutungsrisiko wird diese Empfehlung ausgesprochen. Während des Arztgesprächs sollten zudem Risikofaktoren und Symptome eines thromboembolischen Events thematisiert und Materialien zur Patientenaufklärung ausgehändigt werden.

Abstract

Venous thromboembolism is an important complication in tumour patients as it occurs frequently in these patients and causes relevant morbidity. The risk of thromboembolic complications in tumour patients is 3–9 times higher than in non-tumour patients and is the second most common cause of death in tumour patients. The risk of thrombosis depends on tumour-induced coagulopathy and on individual factors, type and stage of cancer, time since cancer diagnosis as well as type of systemic cancer therapy. Thromboprophylaxis in tumour patients is effective but can be associated with increased bleeding. Even though there are currently no dedicated recommendations for individual tumour entities, international guidelines recommend prophylactic measures in high-risk patients. A thrombosis risk of >8–10% can be considered an indication for thromboprophylaxis, which is indicated by a Khorana score ≥2, and should be calculated individually using nomograms. In particular, patients with a low risk of bleeding should receive thromboprophylaxis. Risk factors and symptoms of a thromboembolic event should also be intensively discussed with the patient and materials for patient information should be handed out.

Fazit für die Praxis

• Thromboembolischen Komplikationen treten bei Tumorpatienten gehäuft auf und können eine relevante Morbidität bedingen.

• Das Thromboserisiko hängt neben der tumorinduzierten Koagulopathie von individuellen Faktoren, der Art und dem Stadium der Krebserkrankung, der Zeit seit der Krebsdiagnose sowie der Art einer systemischen Krebstherapie ab.

• Internationale Leitlinien empfehlen prophylaktische Maßnahmen bei Hochrisikopatienten, dezidierte Empfehlungen für einzelne Tumorentitäten liegen jedoch aktuell nicht vor.

• Eine Thromboseprophylaxe bei Tumorpatienten ist wirksam, kann jedoch mit erhöhten Blutungen einhergehen.

• Eine primäre Thromboseprophylaxe mit NMH oder DOAKs kann bei ambulanten und stationären Tumorpatienten mit hohem Risiko anhand validierter Risikomodelle erwogen werden.

• Risikofaktoren der Thromboseentstehung sowie Symptome eines thromboembolischen Events sollten im Patientengespräch detailliert thematisiert werden.

Schlüsselwörter

venöse thromboembolische Komplikationen - urogenitale Tumore - Thrombosprophylaxe

Keywords

venous thromboembolic events - genitourinary cancer - thromboembolic prophylaxis

Publication History

Received: 17 February 2023

Accepted after revision: 22 May 2023

Article published online:
20 June 2023

• Literatur

• 1 Donnellan E, Khorana AA. Cancer and Venous Thromboembolic Disease: A Review. Oncologist 2017; 22: 199-207
• 2 Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. Cancer Treat Res 2019; 179: 11-36
• 3 Piketty A-C, Fléchon A, Laplanche A. et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93: 909-914
• 4 Heidegger I, Porres D, Veek N. et al. Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer. Urol Int 2017; 99: 104-109
• 5 Gizzi M, Oberic L, Massard C. et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer 2016; 69: 151-157
• 6 Solari L, Krönig M, Ihorst G. et al. High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy. Urol Int 2016; 96: 399-405
• 7 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907
• 8 Srikanthan A, Tran B, Beausoleil M. et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 2015; 33: 582-587
• 9 Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E. et al. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Med 2020; 9: 116-124
• 10 Paffenholz P, Grein K, Heidegger I. et al. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol 2019; 37: 1907-1916
• 11 Bezan A, Posch F, Ploner F. et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One 2017; 12: e0176283
• 12 Duivenvoorden WCM, Daneshmand S, Canter D. et al. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. J Urol 2016; 196: 1627-1633
• 13 Brennan K, Karim S, Doiron RC. et al. Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. Bl cancer (Amsterdam, Netherlands) 2018; 4: 419-428
• 14 Falanga A, Ay C, Di Nisio M. et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol Off J Eur Soc Med Oncol 2023; 34: 452-467
• 15 Balabanova Y, Farahmand B, Garmo H. et al. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open 2022; 12: e055485
• 16 Wysokinski WE, Houghton DE, Vlazny DT. et al. Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism. Thromb Res 2023; 221: 37-44
• 17 Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-981
• 18 Lyman GH, Culakova E, Poniewierski MS. et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018; 164: S112-S118
• 19 Soff G. Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview. Cancer Treat Res 2019; 179: 1-9
• 20 Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-378
• 21 Seng S, Liu Z, Chiu SK. et al. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. J Clin Oncol 2012; 30: 4416-4426
• 22 Nuver J, Smit AJ, Sleijfer DT. et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-706
• 23 Gietema JA, Meinardi MT, Messerschmidt J. et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet (London, England) 2000; 355: 1075-1076
• 24 Falanga A, Russo L, Milesi V. et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol 2017; 118: 79-83
• 25 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5: e289-e298
• 26 Matzdorff A, Ledig B, Stuecker M RH. Practice Patterns for Prophylaxis and Treatment of Venous Thromboembolism in German Cancer Patients. Oncol Res Treat 2016; 39
• 27 Nestler T, Huber J, Laury AM. et al. Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries. World J Urol 2018; 36: 913-920
• 28 van der Wall SJ, Klok FA, den Exter PL. et al. Continuation of Low-Molecular-Weight Heparin Treatment for Cancer-Related Venous Thromboembolism: A Prospective Cohort Study in Daily Clinical Practice. J Thromb Haemost 2017; 15: 74-79
• 29 Carrier M, Abou-Nassar K, Mallick R. et al. Apixaban to Prevent Venous Thromboembolism in Patients With Cancer. N Engl J Med 2019; 380: 711-719
• 30 Khorana AA, Soff GA, Kakkar AK. et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer. N Engl J Med 2019; 380: 720-728
• 31 Key NS, Khorana AA, Kuderer NM. et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38: 496-520
• 32 Chen HTao R, Zhao H. et al. Prevention of Venous Thromboembolism in Patients With Cancer With Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2020; 99: e19000
• 33 Agnelli G, Becattini C, Meyer G. et al. Apixaban for the Treatment of Venous Thromboembolism Associated With Cancer. N Engl J Med 2020; 382: 1599-1607
• 34 Fankhauser CD, Tran B, Pedregal M. et al. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus 2021; 7: 1130-1136
• 35 Honecker F, Koychev D, Luhmann AD. et al. Venous Thromboembolic Events in Germ Cell Cancer Patients Undergoing Platinum-Based Chemotherapy. Onkologie 2013; 36: 7-7
• 36 Fankhauser CD, Oldenburg J, Albers P. et al. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol 2021; 80: 4-6
• 37 Goel A, Khorana A, Kartika T. et al. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. Eur J Haematol 2022; 108: 271-277
• 38 Park H, Jeong CW, Yuk H. et al. Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery. Clin Appl Thromb Hemost 2019; 25
• 39 Naik R, Mandal I, Hampson A. et al. The role of extended venous thromboembolism prophylaxis for major urological cancer operations. BJU Int 2019; 124: 935-944
• 40 Fankhauser CD, Sweeney CJ, Connors JM. Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. Eur Urol 2020; 77: 388-390
• 41 Lyman GH, Khorana AA, Kuderer NM. et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38: 496-520
• 42 Rutjes AWS, Porreca E, Candeloro M. et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane database Syst Rev 2020; 12: CD008500
• 43 Schünemann HJ, Ventresca M, Crowther M. et al. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematol 2020; 7: e746-e755